The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...

Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the ...

The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

Eli Lilly (LLY) stock dropped 3% on Foundayo liver concerns. Analysts say the decline is overdone and recommend buying the ...

Eli Lilly's new oral weight loss drug Foundayo is under scrutiny after an FDA-reported case of liver failure and other ...

Researchers compared the clinical and economic differences between two agents approved to treat metabolic ...

Eli Lilly stock dipped Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout ...

A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

Weight loss drugs are almost everywhere you look, and a new one that could give you results faster might soon hit the market, ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy rating and $1,281 price target for Eli Lilly & Company (NYSE:LLY) shares ...